臺灣細胞治療相關產品商業化之探討：以T生技公司為例

Abstract

21 世紀目前全球正面臨人口過剩、已發展中國家老齡化社會問題、預防性疾病、癌症治療與健康保養意識高漲等，生技產業因此被專家譽為下一個明星產業，而各國政府也積極投入扶植新創生技公司的成長。於生技產業中，除了傳統的藥物開發外，再生醫學中的細胞治療是備受矚目的新型治療方式。科學家們預測這樣的新型治療方式，能解決許多小分子藥物等傳統醫療技術所無法治癒的疾病。台灣於細胞治療領域已經累積一定程度的發展基礎，雖然相關法規起步較晚且尚有許多模糊地帶，但也持續進展並與國際接軌。可惜的是台灣目前沒有任何細胞治療標竿公司可以成為後進者策略模範，也較少過去相關產業的研究資料。因此本研究是以台灣新創細胞治療 T 公司為研究對象，希望在理論基礎的分析架構下，透過相關文獻蒐集整理分析與公司內部訪談等方式，除了對細胞治療產業進行深入了解外，也歸納分析出影響新創細胞治療生技公司的重要關鍵因素，與如何妥善運用限有的資源，並且提出相對應的策略建議。期望本研究能作為研究台灣細胞治療相關產業的前鋒，一同為細胞治療產業貢獻一份心力。

In the 21st century, the whole world is now facing the problem of overpopulation, aging society, disease prevention, caner treatment and the rising of the awareness of public health. The biotechnology is considered to be another star industry, and each government invests progressively the growth of start-up biotech companies. In addition to the traditional drug development in biotech industry, the cell therapy in regeneration medicine is regarded as new type of treatment. Scientists assume this new kind of treatment would be able to cure those diseases that cannot be cured by traditional treatment. Cell therapy in Taiwan has been accumulated some certain levels of development. Although the relevant regulations are started lately and ambiguously, the government progresses step by step to the international standards. However, there is no benchmark standard of cell therapy company in Taiwan, and also few relevant industrial research data could be reach. Therefore, we select T company, a start-up cell therapy company in Taiwan, as our research subject and try to identify those key successful factors, and analyze how to manage those limited resources efficiently to a start-up cell therapy company via literature collection and internal interviews. We propose corresponding strategies and expect this research become the pioneer study in cell therapy related industries in Taiwan.